Sotera Health Analyst Price Targets - Benzinga

Sotera Health Co

SHCNASDAQ

Trade with Public

Trade with Public

$18.15

0.090.5%

마지막 업데이트: Oct 13, 8:29 AM

$18.25

0.191.05%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

Sotera Health Analyst Price Targets - Benzinga

Sotera Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sotera Health (SHC).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

8Buy

1Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$21Upside to Avg. PT+14.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	Citigroup	Brendan Digan	PT Raise	Buy	$23→$25
Aug 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$19→$22
Aug 7, 2026	Piper Sandler	Jason Bednar	PT Raise	Overweight	$22→$25
Aug 7, 2026	JP Morgan	Casey Woodring	PT Raise	Neutral	$16→$18
Jun 24, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$18→$19
Jun 5, 2026	Goldman Sachs	Evie Koslosky	Initiate	Buy	$20
May 6, 2026	Piper Sandler	Jason Bednar	PT Cut	Overweight	$24→$22
Apr 14, 2026	Barclays	Luke Sergott	PT Cut	Overweight	$20→$18
Feb 24, 2026	Citigroup	Patrick Donnelly	PT Raise	Buy	$21→$23
Jan 9, 2026	RBC Capital	Sean Dodge	Reinstates	Outperform	$24
Jan 9, 2026	Piper Sandler	Jason Bednar	Upgrade	Neutral→Overweight	$17→$24
Dec 18, 2025	William Blair	Max Smock	Initiate	Outperform	—
Nov 13, 2025	BMO Capital	Sean Dodge	Initiate	Outperform	$19
Nov 5, 2025	JP Morgan	Casey Woodring	PT Raise	Neutral	$14→$16
Nov 5, 2025	Barclays	Luke Sergott	PT Raise	Overweight	$19→$20
Nov 5, 2025	Piper Sandler	Jason Bednar	PT Raise	Neutral	$15→$17
Oct 2, 2025	Barclays	Luke Sergott	PT Raise	Overweight	$17→$19
Jun 24, 2025	Barclays	Luke Sergott	PT Cut	Overweight	$15→$13
May 5, 2025	Goldman Sachs	Matthew Sykes	Upgrade	Neutral→Buy	$14→$17
Apr 23, 2025	Piper Sandler	Jason Bednar	PT Cut	Neutral	$15→$13

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Buy on Sotera Health, Raises Price Target to $25

Citigroup analyst Brendan Digan maintains Sotera Health (NASDAQ:SHC) with a Buy and raises the price target from $23 to $25.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Sotera Health, Raises Price Target to $22

Barclays analyst Luke Sergott maintains Sotera Health (NASDAQ:SHC) with a Overweight and raises the price target from $19 to $22.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Sotera Health, Raises Price Target to $25

Piper Sandler analyst Jason Bednar reiterates Sotera Health (NASDAQ:SHC) with a Overweight and raises the price target from $22 to $25.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Sotera Health, Raises Price Target to $18

JP Morgan analyst Casey Woodring maintains Sotera Health (NASDAQ:SHC) with a Neutral and raises the price target from $16 to $18.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Sotera Health, Raises Price Target to $19

Barclays analyst Luke Sergott maintains Sotera Health (NASDAQ:SHC) with a Overweight and raises the price target from $18 to $19.

Benzinga Newsdesk

This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Top Wall Street analysts changed outlook for top names. See all changes on analyst ratings page. ONTO rated Buy with $350 PT by Deutsche Bank.

Avi Kapoor